Showing results (351-360 of 531) with videos related to
Sort By:
Pageof 54
Microbiome|May 27, 2024
The interrelation between microbial immunoglobulin coating, vaginal microbiota, ethnicity, and preterm birthH J Schuster, A C Breedveld, S P F Matamoros, et al.Blood|May 13, 2006
Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activityMichal Marzec, Monika Kasprzycka, Raymond Lai, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II resultsFranck Morschhauser, John P Leonard, Luis Fayad, et al.The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 25, 2011
Post-transplant lymphoproliferative disorder after lung transplantation: a review of 35 casesBrandon E Kremer, Ran Reshef, Jamal G Misleh, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 15, 2001
Allogeneic cell therapy for patients who relapse after autologous stem cell transplantationD L Porter, S M Luger, K M Duffy, et al.The Journal of Biological Chemistry|November 10, 2000
Pescadillo, a novel cell cycle regulatory protein abnormally expressed in malignant cellsY Kinoshita, A D Jarell, J M Flaman, et al.EJNMMI Research|March 24, 2025
A biorthogonal chemistry approach for high-contrast antibody imaging of lymphoma at early time pointsSwarbhanu Sarkar, Jonathan M Pham, Kimberly J Edwards, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 13, 2013
Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogrammingMichal Marzec, Krzysztof Halasa, Xiaobin Liu, et al.Leukemia & Lymphoma|December 10, 2020
Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomasNina D Wagner-Johnston, Stephen J Schuster, Sven deVos, et al.British Journal of Haematology|April 25, 2015
Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysisChristina Howlett, Sonya J Snedecor, Daniel J Landsburg, et al.Pageof 54